Warren Chin, DO
Family Medicine · Elmira, NYNPI 1942295183
Payments from drug & device makers
Across 397 payments — averaging $29.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- AstraZeneca$2K
- Novo Nordisk$1K
- Johnson & Johnson$1K
- GSK$723
- Pfizer$609
- plus $4K from 32 others
What the payments were for
- Food & beverage$11,626100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 96 | $2,407 |
| AstraZeneca | 42 | $1,613 |
| Novo Nordisk | 35 | $1,239 |
| Johnson & Johnson | 23 | $1,085 |
| GSK | 22 | $723 |
| Pfizer | 49 | $609 |
| Amgen | 8 | $539 |
| Biohaven Pharmaceuticals, Inc. | 6 | $388 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $332 |
| Biohaven Pharmaceutical Holding Company Ltd. | 10 | $238 |
| Kowa Pharmaceuticals America, Inc. | 11 | $176 |
| Abbott | 3 | $175 |
| Exact Sciences | 6 | $174 |
| Lilly USA, LLC | 10 | $173 |
| Neurocrine Biosciences, Inc. | 3 | $145 |
| Otsuka America Pharmaceutical, Inc. | 7 | $139 |
| Boehringer Ingelheim | 5 | $135 |
| Novartis | 7 | $134 |
| Corium, LLC | 7 | $111 |
| Gilead | 5 | $110 |
| Boston Scientific | 2 | $108 |
| Phathom Pharmaceuticals, Inc. | 2 | $106 |
| Actelion Pharmaceuticals US, Inc. | 1 | $88 |
| Xeris Pharmaceuticals, Inc. | 4 | $86 |
| Impel Pharmaceuticals Inc. | 1 | $85 |
| Alkermes, Inc. | 3 | $73 |
| Collegium Pharmaceutical, Inc. | 4 | $70 |
| Merck | 4 | $65 |
| Bayer | 3 | $53 |
| CSL Behring | 1 | $45 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $41 |
| Ferring Pharmaceuticals Inc. | 2 | $35 |
| Eisai Inc. | 2 | $33 |
| Ardelyx, Inc. | 1 | $28 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,626 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 12 | $167,881 |
| EliquisApixaban | 82 | $86,045 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 40 | $30,599 |
| FarxigaDapagliflozin Propanediol | 35 | $28,668 |
| OzempicSemaglutide | 25 | $28,226 |
| XareltoRivaroxaban | 19 | $26,633 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 39 | $21,613 |
| JanuviaSitagliptin Phosphate | 39 | $21,483 |
| VraylarCariprazine Hcl | 15 | $20,785 |
| EntrestoSacubitril/Valsartan | 26 | $19,583 |
| TrulicityDulaglutide | 13 | $13,916 |
| JardianceEmpagliflozin | 17 | $13,123 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 25 | $10,819 |
| Spiriva RespimatTiotropium Bromide | 15 | $7,507 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $6,212 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $609 | $86,04582 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,613 | $54,82385 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $723 | $36,81154 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Spiriva Respimat | $135 | $31,44957 claims |
| Novo NordiskOzempic | $1,239 | $28,22625 claims |
| Johnson & JohnsonXarelto | $1,085 | $26,63319 claims |
| MerckJanuvia | $65 | $21,48339 claims |
| AbbVieVraylar | $2,407 | $20,78515 claims |
| NovartisEntresto | $134 | $19,58326 claims |
| Lilly USA, LLCTrulicity | $173 | $13,91613 claims |
| Teva Pharmaceuticals USA, Inc.Acyclovir | $21 | $1,52911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.
Other family medicine in Elmira
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.